{"ticker": {"uuid": "5cf1d2ae-3cde-4a13-b8da-a4c46fac8d27", "symbol": "SLS", "name": "Sellas Life Sciences Group Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "SELLAS Life Sciences Group Stock Short Interest Falls to 32.33%", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTWNMWngzUmpWWXlNV3ZjOS01ekFRZEthQk9GN2JpZXJ2WW1HZzd4dkRMR3IxcjZZY3Z2NV9nRHpESUJtZ1JCbjJNZC1ybE9Ya3BKbmhsVzRIUTJTeXZ3Z2l5ajk1Y0c2MjluR3c4VkRTQlV1ZjRaMDJSMzF6aFJqMFVVNG9xOF9Cc0FXOWx2WXZYa20zT2RUNzNINXRXS28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T13:28:00+00:00", "published_display": "21 Jul 2026 13:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Jumps Ahead Of CEO\u2019s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War", "summary": "Shares of Sellas Life Sciences (SLS) increased following speculation among retail traders that the final acute myeloid leukemia (AML) readout, coupled with CEO Angelos Stergiou's upcoming Fox appearance, could attract Big Pharma interest. The company's Phase 3 Regal trial for gal", "url": "https://finance.yahoo.com/markets/stocks/articles/sls-stock-jumps-ahead-ceo-030059721.html", "source_name": "Market source", "published_at": "2026-07-20T02:39:30", "published_display": "20 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints", "summary": "Sellas Life Sciences (SLS) stock is experiencing a significant surge as the company approaches a critical Phase 3 AML study readout and prepares for several investor conferences. The Phase 3 Regal study for acute myeloid leukemia is just two events away from final analysis, and t", "url": "https://stocktwits.com/news-articles/markets/equity/sls-stock-conference-season-investors-aml-readout-hints/cZXlLCvReSN", "source_name": "Stocktwits", "published_at": "2026-07-19T08:09:34", "published_display": "19 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Trades At A Premium On Book Value Despite A 7x Return", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T03:38:59+00:00", "published_display": "19 Jul 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrative", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/near-complete-regal-phase-3-210808813.html", "source_name": "Simply Wall St.", "published_at": "2026-07-18T21:08:08+00:00", "published_display": "18 Jul 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results", "summary": "SELLAS Life Sciences Group (NASDAQ:SLS) saw a 12.3% surge on Friday, reaching $13.19, which highlighted a significant $319 million discrepancy in its market capitalization calculations. This deficit arises from differing share counts used for valuation (weighted average vs. repor", "url": "https://ts2.tech/en/sellas-life-sciences-group-nasdaqsls-surge-draws-attention-to-319-million-market-cap-deficit-ahead-of-regal-trial-results/", "source_name": "TechStock\u00b2", "published_at": "2026-07-18T14:39:57", "published_display": "18 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSE0wTFVrZ1NRakI5eXlCZkcxSmFDd1J3MjZBQVliY2VwWEwzcE1yZ3hiMFU4V0pJNUhvVkd4WEZOemZFdUYtQTNjR051MDFnN2twR1dqaU9QcUZjQXFOcnJlUnU3T3lpZDhFOVdFU2FGNVZiZFZZWF9TYzNJU0l5aEhVRWVzOF9lcFE0YnBwZFo3OHFjVmpTb05HWQ?oc=5", "source_name": "Market source", "published_at": "2026-07-18T08:08:55+00:00", "published_display": "18 Jul 2026 08:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPbGtkUlJHd1QxaHhUd2VQdHZJck50TVMtZXBmZ0MxOTNCSE5iMWEzd00tVW94U0hJR1hxQkFYSHZwT1R0UGJfMU4zUVEwcHQta3hDN1JQaTRHUGF1QVJOZTNOc0tNclVYdklEZ0VFclViUGRGdDNOZ3lOSmNxVWtwQ2RQT3VoTDc1ckFnQWkxYzhqUmJCeHc?oc=5", "source_name": "Market source", "published_at": "2026-07-18T06:09:00+00:00", "published_display": "18 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (NASDAQ:SLS) Shares Climb 12% as Estimated Equity Value Rises $1.6 Billion Since May", "summary": "SELLAS Life Sciences (NASDAQ:SLS) saw its shares climb 12.3% on Friday, reaching $13.19, contributing to a $1.62 billion increase in its estimated equity value since May. This rebound follows earlier drops in the week, with the equity value now standing at approximately $2.59 bil", "url": "https://ts2.tech/en/sellas-life-sciences-nasdaqsls-shares-climb-12-as-estimated-equity-value-rises-1-6-billion-since-may/", "source_name": "TechStock\u00b2", "published_at": "2026-07-17T22:10:56", "published_display": "17 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life (SLS) Climbs 12% Ahead of \u2018Potentially Company-Defining\u2019 Clinical Trial Result", "summary": "Sellas Life Sciences (SLS) stock rose 12% following anticipation of key clinical trial results for its Galinpepimut-S (GPS) treatment for acute myeloid leukemia, which is nearing its pre-specified patient death threshold. Investor enthusiasm is also fueled by speculation of a pot", "url": "https://finance.yahoo.com/healthcare/articles/sellas-life-sls-climbs-12-201112315.html", "source_name": "Market source", "published_at": "2026-07-17T20:10:55", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does SELLAS (SLS) Using a $154.6M Shelf Refine Its Path to Self-Funded Oncology Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T17:55:06+00:00", "published_display": "17 Jul 2026 17:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why SELLAS Life Sciences Group (SLS) Stock Is Up Today", "summary": "SELLAS Life Sciences Group (SLS) stock is up 10.5% today, likely driven by anticipation of results from its pivotal Phase 3 REGAL trial in acute myeloid leukemia, with 78 of 80 required events already occurred. The company's strong liquidity and recent bullish analyst target incr", "url": "https://www.quiverquant.com/news/Why+SELLAS+Life+Sciences+Group+%28SLS%29+Stock+Is+Up+Today", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T18:37:00", "published_display": "17 Jul 2026 18:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Pops As Price Target Jumps On REGAL Trial Hopes", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock has seen a significant price target increase from Alliance Global, jumping from $10 to $25 with a reaffirmed Buy rating. This bullish sentiment is largely driven by optimism surrounding the Phase 3 REGAL trial for Galinpepimut-S in acut", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T18:10:56", "published_display": "17 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Climbs As Analyst Upside Targets REGAL Trial", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock rose over 10% following Alliance Global raising its price target to $25 from $10, driven by optimism around the Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia. The extended timeline for the trial's required deaths is i", "url": "https://timothysykes.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_17/", "source_name": "timothysykes.com", "published_at": "2026-07-17T11:32:00", "published_display": "17 Jul 2026 11:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SELLAS Life Sciences Group (SLS) After REGAL Trial Progress Is It A Buy Or Pricedy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNTF9DX2ZrQmhJeFkwaU0xUW9taEZTUzlzaU81eUVCR1lPX2pfMWFYVndvQWdLWDhfLWhqUlVyaU14cy1Vcm94TDBlcUZOSjlDbmdSNmFMNEtRM2QwUXJrQ3ZzaktZQUhRTXVwWkNtTktaN0lCRWxkUGk0VEJSTUdoUFpZN2tZbXhiS3NwRkhjNjRzU1lCYk9qSjlHUHRhOURSRVV6aTQ2NzNpUXdjUEF6M05JTmVrQ3BwYXQ1VEEzZlByN1JYeXJPNi1ieHFwTFhIMXZRdGU1aXloUnh3U1lJcnpQMGJtdnRYRlVNTVdCSkzSAfYBQVVfeXFMTnc1MVg4SjAxRjlUajZpVFBTZ19abGRJS0dBcDBINWRqTTBhQURTQmZoeGYtRXU2UGtuazFXN1c0RGd6TXpKMi1CS25WSnRBN014UVg2X05odEtrRWpaZ1ZxSTIxbUNWMVVTYm5kdzIzVGZmUzQ0ZlpCTko0OWFHdG91VjdIdndpWjk3YkRsajlVZlRTdTVXcEk1VHFaNmtKZjBpRmhTanRPVURFSE9xbndqNkFnU3NjUXF0emxfZnFMSmRpMkJDMlJIS25YTDJGRXFaMHVJc0Q1M1JJelZiUjZuZjBSWkhHT2I1ZFZRWF9Fa2JXLUZ3?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T15:45:25+00:00", "published_display": "15 Jul 2026 15:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Jumps Overnight After New Investor Disclosure \u2013 Retail Flags \u2018Massive\u2019 Options Bet Ahead Of AML Data", "summary": "Sellas Life Sciences (SLS) stock saw a 1% overnight increase, driven by a new institutional investment from Armstrong Advisory Group, which reported a new position of 380 shares. This rise also follows attention from retail traders who have flagged significant call options activi", "url": "https://es.tradingview.com/news/stocktwits:dd344b330094b:0-sls-stock-jumps-overnight-after-new-investor-disclosure-retail-flags-massive-options-bet-ahead-of-aml-data/", "source_name": "TradingView", "published_at": "2026-07-14T22:41:50", "published_display": "14 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Galinpepimut-S REGAL Readout and Deal Chatter Might Change The Case For Investing In SELLAS (SLS)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T12:31:02+00:00", "published_display": "09 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQUkpfTVg3UWtMUmJwcF9ib2ptOF8tNHNmbXJaZ0Z1U2FzVHdON09waldpV1o4cVpiQnRvZ1dWZ3JMQkRIUDVqOWllLTVQZHF0YmxHUlNfZFVKaUZDRUp5SGRlN0tDTjRaR0lqQm95SEx1UVAxeWMxTVJhTTBLOWpqSUJuTmNsZ0gwZXpjb3JwNDU1QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why SELLAS Life Sciences Group (SLS) Stock Is Down Today", "summary": "This article explains why SELLAS Life Sciences Group (SLS) stock has experienced a decline today. It delves into the specific factors and news that have negatively impacted the company's stock performance.", "url": "https://www.moomoo.com/news/post/72688265/why-sellas-life-sciences-group-sls-stock-is-down-today", "source_name": "Moomoo", "published_at": "2026-07-09T05:48:54", "published_display": "09 Jul 2026 05:48", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Sees Worst Day In Over A Month \u2014 But Prediction Market Flashes 83% Odds For November AML Trial Success", "summary": "Shares of Sellas Life Sciences (SLS) experienced their worst day in over a month, sliding 10% to $13.27, despite a clinical-trials prediction market indicating an 83% probability of success for their GPS therapy in acute myeloid leukemia (AML). The prediction market projects Nove", "url": "https://stocktwits.com/news-articles/markets/equity/sls-prediction-market-odds-november-aml-trial-success/cZme3zFR71q", "source_name": "Stocktwits", "published_at": "2026-07-09T00:09:39", "published_display": "09 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock has experienced significant volatility, trading down 9.11% after a surge fueled by WallStreetBets social media buzz. Despite recent gains of 18% and 7% premarket without fundamental company news, the stock's price action is driven by sp", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T17:40:15", "published_display": "08 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall", "summary": "SELLAS Life Sciences (SLS) shares experienced volatility and slipped on Wednesday, trading lower as the stock encountered a $16 resistance level. Despite the recent dip, the company maintains a bullish outlook, with its stock trading significantly above major moving averages. Thi", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60335899/sellas-life-sciences-shares-slip-wednesday-as-price-tests-16-resistance-wall", "source_name": "Benzinga", "published_at": "2026-07-08T14:40:15", "published_display": "08 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment", "summary": "Sellas Life Sciences (SLS) is experiencing strong retail investor interest, with 50% of 3,400 polled users favoring the stock, driven by the nearing completion of its Phase 3 Regal trial for acute myeloid leukemia. Speculation around potential acquisitions, fueled by optimistic r", "url": "https://intellectia.ai/news/stock/sellas-life-sciences-stock-gains-retail-trader-favor-amid-bullish-sentiment", "source_name": "Intellectia AI", "published_at": "2026-07-07T08:39:56", "published_display": "07 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth", "summary": "This article analyzes SELLAS Life Sciences Group's financial position, specifically its cash reserves and burn rate. It concludes that despite having substantial cash, the company's high burn rate means it can only fund current operations for a little over a year without seeking ", "url": "https://www.moomoo.com/news/post/72527078/companies-like-sellas-life-sciences-group-nasdaq-sls-can-afford", "source_name": "Moomoo", "published_at": "2026-07-06T13:10:12", "published_display": "06 Jul 2026 13:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Should I Buy", "summary": "This article analyzes Sellas Life Sciences Group Inc (SLS) and recommends it as a speculative buy for long-term investors, citing a bullish technical trend, accelerating insider buying, and positive news regarding clinical trial progress. Despite missing financial data and high e", "url": "https://intellectia.ai/en/stock/SLS/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-07-03T08:39:56", "published_display": "03 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS - SELLAS Life Sciences Group Inc Options", "summary": "This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ", "url": "https://finviz.com/stock?t=SLS&ty=oc&p=w&r=y2&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-02T18:39:55", "published_display": "02 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?", "summary": "SELLAS Life Sciences (NASDAQ: SLS) shares dropped on Tuesday due to early profit-taking following a recent breakout. The stock's previous surge was fueled by an 8-K filing detailing executive employment agreements and anticipation for Phase 3 REGAL trial results for galinpepimut ", "url": "https://www.sahmcapital.com/news/content/sellas-life-sciences-shares-fall-tuesday-whats-driving-the-move-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-02T07:40:50", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today?", "summary": "Shares of Sellas Life Sciences Group Inc. (SLS), BlackBerry Ltd. (BB), and Ouster Inc. (OUST) reached 52-week highs on Monday due to positive catalysts and optimistic growth outlooks. SLS surged anticipating Phase 3 trial results for its AML immunotherapy, BB rose after strong ea", "url": "https://es.tradingview.com/news/stocktwits:758407154094b:0-why-did-sls-bb-oust-stocks-surge-to-52-week-highs-today/", "source_name": "TradingView", "published_at": "2026-06-30T19:09:58", "published_display": "30 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Extends Meme-Style Rally On WallStreetBets Buzz", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock extended a meme-style rally driven by WallStreetBets buzz, not new fundamentals or clinical data. Despite trading down 7.9% on trial-related news, the stock had seen a significant surge, reflecting high volatility common in low-float bi", "url": "https://www.timothysykes.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_30/", "source_name": "Timothy Sykes", "published_at": "2026-06-30T15:39:46", "published_display": "30 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Jumps as Traders Focus on Imminent REGAL Trial Catalyst and Stronger Cash Position", "summary": "SELLAS Life Sciences (SLS) saw its stock price increase significantly as investors anticipate a major catalyst from its upcoming REGAL trial. The company's strengthened cash position, as reported in its Q1 2024 financial results, also contributed to positive investor sentiment. T", "url": "https://www.moomoo.com/news/post/72133903/sellas-life-sciences-jumps-as-traders-focus-on-imminent-regal", "source_name": "Moomoo", "published_at": "2026-06-30T00:10:49", "published_display": "30 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Extends Run As Cash Pile Fuels Speculative Trading", "summary": "SELLAS Life Sciences Group Inc. (SLS) has seen its stock surge due to promising oncology trial progress and its substantial cash reserves, making it attractive for speculative trading. Despite operating at a loss, the company's strong balance sheet with $107.1M in cash against mi", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T16:32:33", "published_display": "29 Jun 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPUFBtVW5nTWJja05TV3pDbTRVcnJNU0E3OGktUl83bXY2MjdXYWktd0ItdTlrUTBJVGpMVjBiendqMzlhTlpDNHFVQWlKSjl1eXFIOUVKdklfNUVRNllBWEFnLVJxeHRXUl9URnk1czZNbnFDN28yOVd2X0NmMFhSNFRmRHdNMW1pMy1XX0tieFhHU2dCMlN1ZUVKZw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SELLAS Life Sciences Group, Inc. \u2013 NASDAQ:SLS", "summary": "This article provides the enterprise value to revenue forward for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS). The information is presented within the context of financial data available on TradingView, specifically under the \"Financials\" section for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:40:29", "published_display": "27 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences: The AML Platform Is More Interesting Than Binary Event (NASDAQ:SLS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRlBISWJaOFVGX1dKX1lUaV9RTXkxVVJpQ2hfVHdoa3BadmxVNUh6LTg4b2VuejNhS1lNa2c3RzZsOVg1QnViTmREWjJFU2JRbXVZRWR6MmVQUjBPNXNBSkRsQ0JSZjdHQ3phUk9leXptSW9KTkgyZXdyRTJfVGhZZFJGN2Y0RFFnVXpkOURKYTNuZmhHc0MwWnhobF95b1VYbHZrdW14RkRtR2NoemFYM3BRSE9GRHFidWJaXw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of SELLAS Life Sciences Group, Inc. \u2013 HAM:RXK3", "summary": "The article focuses on the \"Price to earnings forward\" metric for SELLAS Life Sciences Group, Inc. (HAM:RXK3) on the Hamburg Stock Exchange. Although the content provides extensive navigation and data source information, it explicitly states that the stock market is currently clo", "url": "https://www.tradingview.com/symbols/HAM-RXK3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:49", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (SLS) Stock Soars 17% on Executive Contract Overhaul and M&A Buzz", "summary": "SELLAS Life Sciences (SLS) stock surged over 17% to a new 52-week high after the company revised executive contracts to include change-of-control severance packages and accelerated equity vesting, often signaling potential M&A activity. This comes as the company's critical Phase ", "url": "https://blockonomi.com/sellas-life-sciences-sls-stock-soars-17-on-executive-contract-overhaul-and-ma-buzz/", "source_name": "Blockonomi", "published_at": "2026-06-26T14:11:11", "published_display": "26 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Surges As Cash Pile Fuels Biotech Momentum", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock surged by 14.62% due to advancements in its oncology pipeline. Despite being revenue-light and operating at a loss, the biotech company holds a significant cash reserve of $107.1 million, enabling it to fund trials and drive catalyst-dr", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T12:32:00", "published_display": "26 Jun 2026 12:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter", "summary": "Sellas Life Sciences (SLS) saw its short interest climb to a record high of nearly 33% of the float, fueling speculation of a potential short squeeze among bullish investors. This comes alongside renewed buyout chatter, driven by recent changes to executive severance agreements w", "url": "https://stocktwits.com/news-articles/markets/equity/sls-short-interest-record-high-sellas-buyout-speculation/cZ1cmtsR7g0", "source_name": "Stocktwits", "published_at": "2026-06-26T06:53:00", "published_display": "26 Jun 2026 06:53", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group, Inc. Actuals & Estimates (NASDAQ:SLS)", "summary": "This article provides a detailed overview of SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the stock's significant increase over the last year, its volatility, and upcoming earn", "url": "https://www.tradingview.com/symbols/NASDAQ-SLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:10:30", "published_display": "26 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas (SLS) Extends Rally, New Filing Hints at Company Takeover", "summary": "Sellas Life Sciences (SLS) stock extended its rally for a sixth consecutive session, closing up 14.83% after a regulatory filing suggested a potential company takeover. The filing disclosed amendments to employment and severance agreements for three top executives, providing lump", "url": "https://finance.yahoo.com/markets/stocks/articles/sellas-sls-extends-rally-filing-030930721.html", "source_name": "Market source", "published_at": "2026-06-25T21:09:00", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (NASDAQ: SLS) holders approve directors, auditor and equity plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMm1HaHY3UHl6amlHZUpVWTJEMHBBWlFFM3ljUFlhcmdzbXhUWDVxeVU3TC0zV0pGa3J4MzEzX3dqenFiMHd2ajg3V3FITGE3eEpwM3JFVGwzQ1ltdERfNVRSbHFlT1JRYThJWEtkY3pha25VWC0zZTRScXhqclZBd1FOSWFlOU80Q1lUQVpXTU8xNjYwN3dCLWo0VG9Yc3lLU0diMWxsb1lUZWFWTkJjYWZOZmdCZVhWR1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Nears REGAL AML Data As Investors Weigh High Risk Reward", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SELLAS (NASDAQ: SLS) 2026 proxy seeks 20M-share equity plan increase and director elections", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQU0ZjMWFGZjR1NTduZmZNdDdTb1Z6bWk5MXVyZlhxbVhZTEg0UWVqNHRqRUprUGw5SXVUd0lEUndpWVlUNmpzY0Zkel9EQkpPRXBXQjdlR1lqUHJrbWFITHhKX2RtZFVuMXRVNXFVMW40SWY3MzBuVjV0V3VBQ29PY3Z0b1pkbEZ0VFF1Uzl0TG5OaFJNV2hBODNNSUZpV3ZwUi1lQkhmcWtVMk8yTW92OEEySDRqNzdia3l5am5hUkhZQXls?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZHM4NTlNSVVvWVlhMWFhZDljWnA4VUtubUtGVkpRZnZzRHVwMVY0RTdNaEdmVlF0T29GcGRnUGVqWHpQUGJxNVFZYktXWnNaQ2NYNGZLbnFIbGFfVXMtQWZJdjljcll2dEFTZHV1c05VQVBXNm1qUGJvbHFzM0o4QmJGTHQ5WWdJbXZfSU5HUUJIcndpNnotdWNSd2FJZnY0dHNv?oc=5", "source_name": "Market source", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life Sciences Group : SLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE95ZThBSHd0emZlNElTbFVldDA0TnVzaWZOR2IySnRBOGEydTVyRlJySjA5NG5yakpENUlla3dUMmZjMnpaN1hOUTVvQ0M?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SELLAS Life Sciences Group Stock Short Interest Falls to 32.33%", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOTWNMWngzUmpWWXlNV3ZjOS01ekFRZEthQk9GN2JpZXJ2WW1HZzd4dkRMR3IxcjZZY3Z2NV9nRHpESUJtZ1JCbjJNZC1ybE9Ya3BKbmhsVzRIUTJTeXZ3Z2l5ajk1Y0c2MjluR3c4VkRTQlV1ZjRaMDJSMzF6aFJqMFVVNG9xOF9Cc0FXOWx2WXZYa20zT2RUNzNINXRXS28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T13:28:00+00:00", "published_display": "21 Jul 2026 13:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Jumps Ahead Of CEO\u2019s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War", "summary": "Shares of Sellas Life Sciences (SLS) increased following speculation among retail traders that the final acute myeloid leukemia (AML) readout, coupled with CEO Angelos Stergiou's upcoming Fox appearance, could attract Big Pharma interest. The company's Phase 3 Regal trial for gal", "url": "https://finance.yahoo.com/markets/stocks/articles/sls-stock-jumps-ahead-ceo-030059721.html", "source_name": "Market source", "published_at": "2026-07-20T02:39:30", "published_display": "20 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints", "summary": "Sellas Life Sciences (SLS) stock is experiencing a significant surge as the company approaches a critical Phase 3 AML study readout and prepares for several investor conferences. The Phase 3 Regal study for acute myeloid leukemia is just two events away from final analysis, and t", "url": "https://stocktwits.com/news-articles/markets/equity/sls-stock-conference-season-investors-aml-readout-hints/cZXlLCvReSN", "source_name": "Stocktwits", "published_at": "2026-07-19T08:09:34", "published_display": "19 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Trades At A Premium On Book Value Despite A 7x Return", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T03:38:59+00:00", "published_display": "19 Jul 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrative", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/near-complete-regal-phase-3-210808813.html", "source_name": "Simply Wall St.", "published_at": "2026-07-18T21:08:08+00:00", "published_display": "18 Jul 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results", "summary": "SELLAS Life Sciences Group (NASDAQ:SLS) saw a 12.3% surge on Friday, reaching $13.19, which highlighted a significant $319 million discrepancy in its market capitalization calculations. This deficit arises from differing share counts used for valuation (weighted average vs. repor", "url": "https://ts2.tech/en/sellas-life-sciences-group-nasdaqsls-surge-draws-attention-to-319-million-market-cap-deficit-ahead-of-regal-trial-results/", "source_name": "TechStock\u00b2", "published_at": "2026-07-18T14:39:57", "published_display": "18 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSE0wTFVrZ1NRakI5eXlCZkcxSmFDd1J3MjZBQVliY2VwWEwzcE1yZ3hiMFU4V0pJNUhvVkd4WEZOemZFdUYtQTNjR051MDFnN2twR1dqaU9QcUZjQXFOcnJlUnU3T3lpZDhFOVdFU2FGNVZiZFZZWF9TYzNJU0l5aEhVRWVzOF9lcFE0YnBwZFo3OHFjVmpTb05HWQ?oc=5", "source_name": "Market source", "published_at": "2026-07-18T08:08:55+00:00", "published_display": "18 Jul 2026 08:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPbGtkUlJHd1QxaHhUd2VQdHZJck50TVMtZXBmZ0MxOTNCSE5iMWEzd00tVW94U0hJR1hxQkFYSHZwT1R0UGJfMU4zUVEwcHQta3hDN1JQaTRHUGF1QVJOZTNOc0tNclVYdklEZ0VFclViUGRGdDNOZ3lOSmNxVWtwQ2RQT3VoTDc1ckFnQWkxYzhqUmJCeHc?oc=5", "source_name": "Market source", "published_at": "2026-07-18T06:09:00+00:00", "published_display": "18 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (NASDAQ:SLS) Shares Climb 12% as Estimated Equity Value Rises $1.6 Billion Since May", "summary": "SELLAS Life Sciences (NASDAQ:SLS) saw its shares climb 12.3% on Friday, reaching $13.19, contributing to a $1.62 billion increase in its estimated equity value since May. This rebound follows earlier drops in the week, with the equity value now standing at approximately $2.59 bil", "url": "https://ts2.tech/en/sellas-life-sciences-nasdaqsls-shares-climb-12-as-estimated-equity-value-rises-1-6-billion-since-may/", "source_name": "TechStock\u00b2", "published_at": "2026-07-17T22:10:56", "published_display": "17 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life (SLS) Climbs 12% Ahead of \u2018Potentially Company-Defining\u2019 Clinical Trial Result", "summary": "Sellas Life Sciences (SLS) stock rose 12% following anticipation of key clinical trial results for its Galinpepimut-S (GPS) treatment for acute myeloid leukemia, which is nearing its pre-specified patient death threshold. Investor enthusiasm is also fueled by speculation of a pot", "url": "https://finance.yahoo.com/healthcare/articles/sellas-life-sls-climbs-12-201112315.html", "source_name": "Market source", "published_at": "2026-07-17T20:10:55", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does SELLAS (SLS) Using a $154.6M Shelf Refine Its Path to Self-Funded Oncology Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T17:55:06+00:00", "published_display": "17 Jul 2026 17:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why SELLAS Life Sciences Group (SLS) Stock Is Up Today", "summary": "SELLAS Life Sciences Group (SLS) stock is up 10.5% today, likely driven by anticipation of results from its pivotal Phase 3 REGAL trial in acute myeloid leukemia, with 78 of 80 required events already occurred. The company's strong liquidity and recent bullish analyst target incr", "url": "https://www.quiverquant.com/news/Why+SELLAS+Life+Sciences+Group+%28SLS%29+Stock+Is+Up+Today", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T18:37:00", "published_display": "17 Jul 2026 18:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Pops As Price Target Jumps On REGAL Trial Hopes", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock has seen a significant price target increase from Alliance Global, jumping from $10 to $25 with a reaffirmed Buy rating. This bullish sentiment is largely driven by optimism surrounding the Phase 3 REGAL trial for Galinpepimut-S in acut", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T18:10:56", "published_display": "17 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Climbs As Analyst Upside Targets REGAL Trial", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock rose over 10% following Alliance Global raising its price target to $25 from $10, driven by optimism around the Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia. The extended timeline for the trial's required deaths is i", "url": "https://timothysykes.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_17/", "source_name": "timothysykes.com", "published_at": "2026-07-17T11:32:00", "published_display": "17 Jul 2026 11:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group (SLS) After REGAL Trial Progress Is It A Buy Or Pricedy", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T15:45:25+00:00", "published_display": "15 Jul 2026 15:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Jumps Overnight After New Investor Disclosure \u2013 Retail Flags \u2018Massive\u2019 Options Bet Ahead Of AML Data", "summary": "Sellas Life Sciences (SLS) stock saw a 1% overnight increase, driven by a new institutional investment from Armstrong Advisory Group, which reported a new position of 380 shares. This rise also follows attention from retail traders who have flagged significant call options activi", "url": "https://es.tradingview.com/news/stocktwits:dd344b330094b:0-sls-stock-jumps-overnight-after-new-investor-disclosure-retail-flags-massive-options-bet-ahead-of-aml-data/", "source_name": "TradingView", "published_at": "2026-07-14T22:41:50", "published_display": "14 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galinpepimut-S REGAL Readout and Deal Chatter Might Change The Case For Investing In SELLAS (SLS)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T12:31:02+00:00", "published_display": "09 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQUkpfTVg3UWtMUmJwcF9ib2ptOF8tNHNmbXJaZ0Z1U2FzVHdON09waldpV1o4cVpiQnRvZ1dWZ3JMQkRIUDVqOWllLTVQZHF0YmxHUlNfZFVKaUZDRUp5SGRlN0tDTjRaR0lqQm95SEx1UVAxeWMxTVJhTTBLOWpqSUJuTmNsZ0gwZXpjb3JwNDU1QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why SELLAS Life Sciences Group (SLS) Stock Is Down Today", "summary": "This article explains why SELLAS Life Sciences Group (SLS) stock has experienced a decline today. It delves into the specific factors and news that have negatively impacted the company's stock performance.", "url": "https://www.moomoo.com/news/post/72688265/why-sellas-life-sciences-group-sls-stock-is-down-today", "source_name": "Moomoo", "published_at": "2026-07-09T05:48:54", "published_display": "09 Jul 2026 05:48", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Sees Worst Day In Over A Month \u2014 But Prediction Market Flashes 83% Odds For November AML Trial Success", "summary": "Shares of Sellas Life Sciences (SLS) experienced their worst day in over a month, sliding 10% to $13.27, despite a clinical-trials prediction market indicating an 83% probability of success for their GPS therapy in acute myeloid leukemia (AML). The prediction market projects Nove", "url": "https://stocktwits.com/news-articles/markets/equity/sls-prediction-market-odds-november-aml-trial-success/cZme3zFR71q", "source_name": "Stocktwits", "published_at": "2026-07-09T00:09:39", "published_display": "09 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock has experienced significant volatility, trading down 9.11% after a surge fueled by WallStreetBets social media buzz. Despite recent gains of 18% and 7% premarket without fundamental company news, the stock's price action is driven by sp", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T17:40:15", "published_display": "08 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall", "summary": "SELLAS Life Sciences (SLS) shares experienced volatility and slipped on Wednesday, trading lower as the stock encountered a $16 resistance level. Despite the recent dip, the company maintains a bullish outlook, with its stock trading significantly above major moving averages. Thi", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60335899/sellas-life-sciences-shares-slip-wednesday-as-price-tests-16-resistance-wall", "source_name": "Benzinga", "published_at": "2026-07-08T14:40:15", "published_display": "08 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment", "summary": "Sellas Life Sciences (SLS) is experiencing strong retail investor interest, with 50% of 3,400 polled users favoring the stock, driven by the nearing completion of its Phase 3 Regal trial for acute myeloid leukemia. Speculation around potential acquisitions, fueled by optimistic r", "url": "https://intellectia.ai/news/stock/sellas-life-sciences-stock-gains-retail-trader-favor-amid-bullish-sentiment", "source_name": "Intellectia AI", "published_at": "2026-07-07T08:39:56", "published_display": "07 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth", "summary": "This article analyzes SELLAS Life Sciences Group's financial position, specifically its cash reserves and burn rate. It concludes that despite having substantial cash, the company's high burn rate means it can only fund current operations for a little over a year without seeking ", "url": "https://www.moomoo.com/news/post/72527078/companies-like-sellas-life-sciences-group-nasdaq-sls-can-afford", "source_name": "Moomoo", "published_at": "2026-07-06T13:10:12", "published_display": "06 Jul 2026 13:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Should I Buy", "summary": "This article analyzes Sellas Life Sciences Group Inc (SLS) and recommends it as a speculative buy for long-term investors, citing a bullish technical trend, accelerating insider buying, and positive news regarding clinical trial progress. Despite missing financial data and high e", "url": "https://intellectia.ai/en/stock/SLS/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-07-03T08:39:56", "published_display": "03 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS - SELLAS Life Sciences Group Inc Options", "summary": "This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ", "url": "https://finviz.com/stock?t=SLS&ty=oc&p=w&r=y2&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-02T18:39:55", "published_display": "02 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?", "summary": "SELLAS Life Sciences (NASDAQ: SLS) shares dropped on Tuesday due to early profit-taking following a recent breakout. The stock's previous surge was fueled by an 8-K filing detailing executive employment agreements and anticipation for Phase 3 REGAL trial results for galinpepimut ", "url": "https://www.sahmcapital.com/news/content/sellas-life-sciences-shares-fall-tuesday-whats-driving-the-move-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-02T07:40:50", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today?", "summary": "Shares of Sellas Life Sciences Group Inc. (SLS), BlackBerry Ltd. (BB), and Ouster Inc. (OUST) reached 52-week highs on Monday due to positive catalysts and optimistic growth outlooks. SLS surged anticipating Phase 3 trial results for its AML immunotherapy, BB rose after strong ea", "url": "https://es.tradingview.com/news/stocktwits:758407154094b:0-why-did-sls-bb-oust-stocks-surge-to-52-week-highs-today/", "source_name": "TradingView", "published_at": "2026-06-30T19:09:58", "published_display": "30 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Extends Meme-Style Rally On WallStreetBets Buzz", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock extended a meme-style rally driven by WallStreetBets buzz, not new fundamentals or clinical data. Despite trading down 7.9% on trial-related news, the stock had seen a significant surge, reflecting high volatility common in low-float bi", "url": "https://www.timothysykes.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_30/", "source_name": "Timothy Sykes", "published_at": "2026-06-30T15:39:46", "published_display": "30 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Jumps as Traders Focus on Imminent REGAL Trial Catalyst and Stronger Cash Position", "summary": "SELLAS Life Sciences (SLS) saw its stock price increase significantly as investors anticipate a major catalyst from its upcoming REGAL trial. The company's strengthened cash position, as reported in its Q1 2024 financial results, also contributed to positive investor sentiment. T", "url": "https://www.moomoo.com/news/post/72133903/sellas-life-sciences-jumps-as-traders-focus-on-imminent-regal", "source_name": "Moomoo", "published_at": "2026-06-30T00:10:49", "published_display": "30 Jun 2026 00:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Extends Run As Cash Pile Fuels Speculative Trading", "summary": "SELLAS Life Sciences Group Inc. (SLS) has seen its stock surge due to promising oncology trial progress and its substantial cash reserves, making it attractive for speculative trading. Despite operating at a loss, the company's strong balance sheet with $107.1M in cash against mi", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_29/", "source_name": "StocksToTrade", "published_at": "2026-06-29T16:32:33", "published_display": "29 Jun 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPUFBtVW5nTWJja05TV3pDbTRVcnJNU0E3OGktUl83bXY2MjdXYWktd0ItdTlrUTBJVGpMVjBiendqMzlhTlpDNHFVQWlKSjl1eXFIOUVKdklfNUVRNllBWEFnLVJxeHRXUl9URnk1czZNbnFDN28yOVd2X0NmMFhSNFRmRHdNMW1pMy1XX0tieFhHU2dCMlN1ZUVKZw?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SELLAS Life Sciences Group, Inc. \u2013 NASDAQ:SLS", "summary": "This article provides the enterprise value to revenue forward for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS). The information is presented within the context of financial data available on TradingView, specifically under the \"Financials\" section for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:40:29", "published_display": "27 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences: The AML Platform Is More Interesting Than Binary Event (NASDAQ:SLS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRlBISWJaOFVGX1dKX1lUaV9RTXkxVVJpQ2hfVHdoa3BadmxVNUh6LTg4b2VuejNhS1lNa2c3RzZsOVg1QnViTmREWjJFU2JRbXVZRWR6MmVQUjBPNXNBSkRsQ0JSZjdHQ3phUk9leXptSW9KTkgyZXdyRTJfVGhZZFJGN2Y0RFFnVXpkOURKYTNuZmhHc0MwWnhobF95b1VYbHZrdW14RkRtR2NoemFYM3BRSE9GRHFidWJaXw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of SELLAS Life Sciences Group, Inc. \u2013 HAM:RXK3", "summary": "The article focuses on the \"Price to earnings forward\" metric for SELLAS Life Sciences Group, Inc. (HAM:RXK3) on the Hamburg Stock Exchange. Although the content provides extensive navigation and data source information, it explicitly states that the stock market is currently clo", "url": "https://www.tradingview.com/symbols/HAM-RXK3/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:49", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (SLS) Stock Soars 17% on Executive Contract Overhaul and M&A Buzz", "summary": "SELLAS Life Sciences (SLS) stock surged over 17% to a new 52-week high after the company revised executive contracts to include change-of-control severance packages and accelerated equity vesting, often signaling potential M&A activity. This comes as the company's critical Phase ", "url": "https://blockonomi.com/sellas-life-sciences-sls-stock-soars-17-on-executive-contract-overhaul-and-ma-buzz/", "source_name": "Blockonomi", "published_at": "2026-06-26T14:11:11", "published_display": "26 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Stock Surges As Cash Pile Fuels Biotech Momentum", "summary": "SELLAS Life Sciences Group Inc. (SLS) stock surged by 14.62% due to advancements in its oncology pipeline. Despite being revenue-light and operating at a loss, the biotech company holds a significant cash reserve of $107.1 million, enabling it to fund trials and drive catalyst-dr", "url": "https://stockstotrade.com/news/sellas-life-sciences-group-inc-sls-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T12:32:00", "published_display": "26 Jun 2026 12:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter", "summary": "Sellas Life Sciences (SLS) saw its short interest climb to a record high of nearly 33% of the float, fueling speculation of a potential short squeeze among bullish investors. This comes alongside renewed buyout chatter, driven by recent changes to executive severance agreements w", "url": "https://stocktwits.com/news-articles/markets/equity/sls-short-interest-record-high-sellas-buyout-speculation/cZ1cmtsR7g0", "source_name": "Stocktwits", "published_at": "2026-06-26T06:53:00", "published_display": "26 Jun 2026 06:53", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences Group, Inc. Actuals & Estimates (NASDAQ:SLS)", "summary": "This article provides a detailed overview of SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the stock's significant increase over the last year, its volatility, and upcoming earn", "url": "https://www.tradingview.com/symbols/NASDAQ-SLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:10:30", "published_display": "26 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas (SLS) Extends Rally, New Filing Hints at Company Takeover", "summary": "Sellas Life Sciences (SLS) stock extended its rally for a sixth consecutive session, closing up 14.83% after a regulatory filing suggested a potential company takeover. The filing disclosed amendments to employment and severance agreements for three top executives, providing lump", "url": "https://finance.yahoo.com/markets/stocks/articles/sellas-sls-extends-rally-filing-030930721.html", "source_name": "Market source", "published_at": "2026-06-25T21:09:00", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Life Sciences (NASDAQ: SLS) holders approve directors, auditor and equity plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMm1HaHY3UHl6amlHZUpVWTJEMHBBWlFFM3ljUFlhcmdzbXhUWDVxeVU3TC0zV0pGa3J4MzEzX3dqenFiMHd2ajg3V3FITGE3eEpwM3JFVGwzQ1ltdERfNVRSbHFlT1JRYThJWEtkY3pha25VWC0zZTRScXhqclZBd1FOSWFlOU80Q1lUQVpXTU8xNjYwN3dCLWo0VG9Yc3lLU0diMWxsb1lUZWFWTkJjYWZOZmdCZVhWR1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS Nears REGAL AML Data As Investors Weigh High Risk Reward", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SELLAS (NASDAQ: SLS) 2026 proxy seeks 20M-share equity plan increase and director elections", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQU0ZjMWFGZjR1NTduZmZNdDdTb1Z6bWk5MXVyZlhxbVhZTEg0UWVqNHRqRUprUGw5SXVUd0lEUndpWVlUNmpzY0Zkel9EQkpPRXBXQjdlR1lqUHJrbWFITHhKX2RtZFVuMXRVNXFVMW40SWY3MzBuVjV0V3VBQ29PY3Z0b1pkbEZ0VFF1Uzl0TG5OaFJNV2hBODNNSUZpV3ZwUi1lQkhmcWtVMk8yTW92OEEySDRqNzdia3l5am5hUkhZQXls?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZHM4NTlNSVVvWVlhMWFhZDljWnA4VUtubUtGVkpRZnZzRHVwMVY0RTdNaEdmVlF0T29GcGRnUGVqWHpQUGJxNVFZYktXWnNaQ2NYNGZLbnFIbGFfVXMtQWZJdjljcll2dEFTZHV1c05VQVBXNm1qUGJvbHFzM0o4QmJGTHQ5WWdJbXZfSU5HUUJIcndpNnotdWNSd2FJZnY0dHNv?oc=5", "source_name": "Market source", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sellas Life Sciences Group : SLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE95ZThBSHd0emZlNElTbFVldDA0TnVzaWZOR2IySnRBOGEydTVyRlJySjA5NG5yakpENUlla3dUMmZjMnpaN1hOUTVvQ0M?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 55, "sentiment_summary": {"positive": 23, "negative": 8, "neutral": 24, "score": 58, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 13.19, "latest_week": "2026-07-17", "one_week_move": 3.4, "four_week_move": 63.9, "twelve_week_move": 195.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.509456, "market_dynamics_buy_signal": false, "relative_strength": 181.401187, "fair_value_gap": 472.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.0338, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.4% over one week, +63.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "simplywall.st", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "StocksToTrade", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "TechStock\u00b2", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.4% over one week, +63.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "SELLAS Life Sciences Group Stock Short Interest Falls to 32.33%"}], "updated_at": "2026-07-22T07:08:18.145377+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}